首页> 外文期刊>Acta crystallographica.Section D. Biological crystallography >Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: Binding details and inhibition mechanism
【24h】

Structures of human sirtuin 3 complexes with ADP-ribose and with carba-NAD+ and SRT1720: Binding details and inhibition mechanism

机译:人类sirtuin蛋白3复合体的结构ADP-ribose carba-NAD +和SRT1720:绑定细节和抑制机制

获取原文
获取原文并翻译 | 示例
           

摘要

Sirtuins are NAD+-dependent protein deacetylases that regulate metabolism and aging processes and are considered to be attractive therapeutic targets. Most available sirtuin modulators are little understood mechanistically, hindering their improvement. SRT1720 was initially described as an activator of human Sirt1, but it also potently inhibits human Sirt3. Here, the molecular mechanism of the inhibition of Sirt3 by SRT1720 is described. A crystal structure of Sirt3 in complex with SRT1720 and an NAD+ analogue reveals that the compound partially occupies the acetyl-Lys binding site, thus explaining the reported competition with the peptide substrate. The compound packs against a hydrophobic protein patch and binds with its opposite surface to the NAD+ nicotinamide, resulting in an exceptionally tight sandwich-like interaction. The observed arrangement rationalizes the uncompetitive inhibition with NAD+, and binding measurements confirm that the nicotinamide moiety of NAD+ supports inhibitor binding. Consistently, no inhibitor is bound in a second crystal structure of Sirt3 that was solved complexed with ADP-ribose and crystallized in the presence of SRT1720. These results reveal a novel sirtuin inhibitor binding site and mechanism, and provide a structural basis for compound improvement.
机译:Sirtuins蛋白NAD +端依赖蛋白去乙酰酶抑制剂调节新陈代谢和衰老过程被认为是有吸引力的治疗目标。知之甚少的机械化,阻碍他们的进步。描述为一个人类Sirt1激活剂,但它人类Sirt3也强有力地抑制。Sirt3的抑制的分子机制SRT1720描述。Sirt3和SRT1720复杂和NAD +模拟表明,复合部分占据了acetyl-Lys结合位点,因此解释了竞争与报道肽底物。并结合其疏水性蛋白补丁相反的表面NAD +烟酰胺,导致异常紧张的一张交互。密切竞争力抑制NAD +,绑定测量确认烟酰胺的一部分NAD +支持抑制剂绑定。第二,Sirt3的晶体结构解决包裹着ADP-ribose和结晶SRT1720的存在。sirtuin蛋白抑制剂结合位点和机制提供一个结构化合物的基础改进。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号